Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 143 entries
View as:

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02136888 Org: User:
Start: 08/31/11 End: 02/29/12 Due: 02/28/13

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Phase: N/A Priority: Normal
NCT ID: NCT03775421 Org: User:
Start: 04/11/19 End: 01/18/22 Due: 01/18/23

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

Phase: N/A Priority: Normal
NCT ID: NCT04955990 Org: User:
Start: 10/14/21 End: 12/20/22 Due: 12/20/23

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT00086463 Org: User:
Start: 06/30/04 End: 01/31/06 Due: 01/31/07

BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Phase: N/A Priority: Normal
NCT ID: NCT00367770 Org: User:
Start: 01/31/04 End: 12/31/05 Due: 12/31/06

Open-label Study With Bosentan in Interstitial Lung Disease

Phase: N/A Priority: Normal
NCT ID: NCT00319033 Org: User:
Start: 07/31/04 End: 02/28/06 Due: 02/28/07

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00537602 Org: User:
Start: 11/30/07 End: 03/31/08 Due: 03/31/09

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

Phase: N/A Priority: Normal
NCT ID: NCT02968901 Org: User:
Start: 09/01/15 End: 09/10/18 Due: 09/10/19

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Phase: N/A Priority: Normal
NCT ID: NCT02461134 Org: User:
Start: 09/29/16 End: 03/03/17 Due: 03/03/18

Iloprost Power 15 in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00709956 Org: User:
Start: 07/31/08 End: 08/31/09 Due: 08/31/10

Epoprostenol for Injection in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01105091 Org: User:
Start: 03/31/10 End: 07/31/11 Due: 07/31/12

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03689244 Org: User:
Start: 01/23/19 End: 06/07/22 Due: 06/07/23

A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

Phase: N/A Priority: Normal
NCT ID: NCT02081690 Org: User:
Start: 03/01/14 End: 11/01/15 Due: 11/01/16

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00071461 Org: User:
Start: 08/31/03 End: 05/31/10 Due: 05/31/11

A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02770222 Org: User:
Start: 06/30/16 End: 07/31/16 Due: 07/31/17

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02745860 Org: User:
Start: 06/30/16 End: 06/30/16 Due: 06/30/17

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

Phase: N/A Priority: Normal
NCT ID: NCT04565990 Org: User:
Start: 05/03/21 End: 11/10/23 Due: 11/10/24

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)

Phase: N/A Priority: Normal
NCT ID: NCT00313196 Org: User:
Start: 04/30/06 End: 08/31/07 Due: 08/31/08

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT03714815 Org: User:
Start: 12/07/18 End: 10/12/21 Due: 10/12/22

A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study

Phase: N/A Priority: Normal
NCT ID: NCT00360087 Org: User:
Start: 03/31/06 End: 12/31/07 Due: 12/31/08

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT00903331 Org: User:
Start: 05/31/09 End: 08/31/11 Due: 08/31/12

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02126956 Org: User:
Start: 03/31/09 End: 04/30/09 Due: 04/30/10

Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Phase: N/A Priority: Normal
NCT ID: NCT01222702 Org: User:
Start: 01/25/11 End: 11/12/12 Due: 11/12/13

Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection

Phase: N/A Priority: Normal
NCT ID: NCT02053181 Org: User:
Start: 08/31/12 End: 09/30/12 Due: 09/30/13

ACT-128800 in Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00852670 Org: User:
Start: 10/31/08 End: 09/30/09 Due: 09/30/10